Plain-English translation of NCT07011056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether is more effective and safer than an existing treatment called selinexor for people with relapsed or refractory diffuse large B-cell lymphoma (an aggressive type of blood cancer). About 390 patients will be randomly assigned to receive either the new medication or the existing treatment. Researchers will compare how well each treatment works and monitor side effects.
Currently, patients whose lymphoma returns or stops responding to standard treatments have limited options. This medication may offer a new way to help these patients, and researchers want to see if it works better than the current standard treatment available to them.
You likely qualify if…
You likely don't qualify if…
If you're randomly assigned to receive the new medication, you'll receive intravenous injections on specific days over a 6-cycle treatment period (about 18 weeks total). If you're in the comparison group, you'll take an oral medication twice per week for 4-week cycles. Either way, you'll have regular clinic visits for blood tests, scans, and check-ins to monitor how the treatment is working and watch for side effects.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China